New hope for rare breast condition: drug targets stubborn inflammation
NCT ID NCT07595900
First seen May 20, 2026 · Last updated Jun 19, 2026 · Updated 5 times
Summary
This early-stage trial tests whether tocilizumab, an anti-inflammatory drug, can help women with a rare breast condition called granulomatous lobular mastitis that hasn't improved with steroids. About 31 women aged 20-50 will receive two doses of the drug intravenously. The main goal is to see if inflammation goes down within 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOUS MASTITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks IL-6, a protein involved in inflammation)
What this could lead to
If successful, this could provide a new treatment option for people with a rare, painful breast condition that doesn't respond to steroids.
What could go wrong
This is a very early, small trial (31 people) with no comparison group, so results may not be conclusive. Tocilizumab also has known risks like serious infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.